# A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

> **NCT05013424** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 92 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** Formulation A: OnabotulinumtoxinA
- **DRUG:** Formulation B: OnabotulinumtoxinA
- **DRUG:** Formulation C: OnabotulinumtoxinA

## Key facts

- **NCT ID:** NCT05013424
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-07-07
- **Final completion:** 2022-07-07
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013424, "A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05013424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*